AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Recent research efforts aimed at curing Pantothenate Kinase-Associated Neurodegeneration (PKAN).

Last updated

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Overview

Pantothenate Kinase-Associated Neurodegeneration (PKAN) is an ultra-rare inherited disorder caused by disease-causing changes in both copies of the PANK2 gene. The missing or impaired PANK2 enzyme disrupts production of coenzyme A (CoA), a molecule needed for energy metabolism and many other cell functions. PKAN is part of the neurodegeneration with brain iron accumulation (NBIA) disorders; it commonly causes iron accumulation in deep brain regions involved in movement. Classic PKAN usually begins in early childhood with worsening dystonia (painful involuntary twisting movements), stiffness, speech and swallowing problems, and often retinal degeneration. Atypical PKAN usually begins after age 10 and progresses more slowly, with speech, psychiatric, and movement symptoms. PKAN GeneReviews (ncbi.nlm.nih.gov)

PKAN is progressive and can lead to severe loss of mobility, communication, independence, and nutrition; prognosis varies considerably by age at onset and residual enzyme activity. There is no approved treatment that corrects the underlying genetic or metabolic defect. Current care is multidisciplinary and symptom-focused: medicines such as baclofen, trihexyphenidyl, clonazepam, and botulinum toxin can reduce dystonia for some people; physical, occupational, speech, swallowing, eye, nutritional, and respiratory care address complications; and deep-brain stimulation may provide symptomatic benefit for selected patients, although it does not stop disease progression. PKAN GeneReviews (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has become more biologically targeted, moving beyond attempts to remove accumulated iron toward restoring CoA metabolism upstream of the injury cascade. The principal questions are whether a CoA-pathway intermediate can safely bypass the PANK2 block, whether activating the related PANK3 enzyme can compensate for PANK2 loss, and whether gene replacement can deliver sufficient PANK2 activity to vulnerable brain cells. As of October 3, 2026, the field has credible disease-modifying candidates and active or recently completed early-phase studies, but no therapy has yet demonstrated that it halts, reverses, or cures PKAN in patients. Precision medicine update (movementdisorders.onlinelibrary.wiley.com)

Major Breakthroughs and Emerging Therapies

The leading clinical strategy is metabolic bypass with 4′-phosphopantetheine (4′-PPT), also called CoA-Z in the U.S. program. 4′-PPT is a downstream intermediate in CoA production that can bypass the defective PANK2 reaction. In PANK2-deficient mouse and patient-cell studies, oral 4′-PPT restored CoA-pathway markers, corrected abnormalities in iron- and dopamine-related markers, and improved mitochondrial enzyme activity. These results are important because they connect the genetic defect to measurable biological markers that can be followed during human trials. 4′-PPT mammalian-model study (link.springer.com)

A second strategy is to activate PANK3, a related pantothenate kinase that can potentially substitute for missing PANK2 activity. BBP-671, a brain-penetrant allosteric PANK activator, raised brain CoA levels and improved movement and survival in a mouse model of PKAN. Its first-in-human program was not a PKAN trial and was terminated, but the preclinical result established that pharmacologically increasing PANK activity can correct brain CoA deficiency. BBP-671 mouse study Precision medicine update (pubmed.ncbi.nlm.nih.gov)

More recently, researchers reported a new class of selective, orally bioavailable PANK3 activators called VTACs. In cell and mouse models of PANK2 deficiency, the lead compound VTAC-2 restored CoA to wild-type levels in cells and mouse brain. This is an encouraging preclinical advance because the compounds are designed to enter the central nervous system and compensate for PANK2 loss without replacing the gene itself; however, they remain preclinical and have not yet shown benefit in people with PKAN. VTAC-2 preclinical study (pubmed.ncbi.nlm.nih.gov)

Additional approaches remain earlier in development. Stable derivatives such as acetyl-4′-phosphopantetheine and cyclic phosphopantothenic acid aim to improve delivery and persistence of CoA-pathway metabolites. Gene replacement using adeno-associated virus (AAV) vectors is considered a rational long-term strategy because PKAN results from loss of a single gene, but PKAN gene therapy remains early preclinical research rather than a registered human clinical program. Precision medicine update Therapy redesign review (movementdisorders.onlinelibrary.wiley.com)

Clinical Trials and Experimental Approaches

The most advanced current metabolic-bypass program is CoA-Z/4′-PPT. The Oregon Health & Science University-led U.S. Phase 2 study, NCT04182763, tested multiple oral CoA-Z doses against placebo followed by open-label treatment. The registry lists the study as completed, with 77 enrolled participants and results posted in October 2025; a recent review describes safety, tolerability, and dose-dependent biomarker responses, but a full peer-reviewed clinical efficacy report has not yet established whether CoA-Z changes long-term function or disease progression. NCT04182763 trial record Precision medicine update (ctv.veeva.com)

A separate U.K. Phase II study of oral or enteral UK-PKAN-B5D, a 4′-PPT product, is ongoing but no longer recruiting. It plans a 24-week randomized, double-blind, placebo-controlled period followed by 24 weeks of open-label treatment, with safety, PKAN-specific activities-of-daily-living and disease-rating scales, blood biomarkers, eye measures, dystonia, and quality of life among the outcomes; its registered completion date is March 31, 2027. ISRCTN10664670 trial record (isrctn.com)

Recent negative or inconclusive studies have sharpened the field’s focus. In a 2020 randomized controlled trial, fosmetpantotenate, a different phosphopantothenate-replacement prodrug, did not improve the primary PKAN activities-of-daily-living endpoint or secondary motor outcomes over 24 weeks, and its development was discontinued. A 2020 open-label pediatric pantethine study likewise did not show clear improvement in serum CoA or primary clinical outcomes, although exploratory findings suggested a possible slowing of motor decline; a later three-patient supplement study reported tolerability and possible slowing of deterioration but could not demonstrate significant motor improvement. Fosmetpantotenate trial Pantethine pilot trial Multitarget supplement pilot (pubmed.ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

PKAN researchers combine patient-derived fibroblasts, induced neuronal models, red blood cells, and genetically modified mice to test whether therapies restore CoA metabolism and downstream cell functions. These platforms measure CoA-pathway gene expression, mitochondrial respiration, complex I and pyruvate dehydrogenase activity, oxidative stress, lipid damage, dopamine-related markers, and iron-homeostasis markers. The goal is to find pharmacodynamic biomarkers—measures that show a drug is hitting its biological target—because observable neurological changes can take years and vary markedly among patients. 4′-PPT mammalian-model study Rare-disease trial-design analysis (link.springer.com)

Clinical studies increasingly use PKAN-specific functional scales, standardized dystonia ratings, caregiver-reported outcomes, blinded video assessments, MRI measures of brain iron, eye assessments, and blood-based metabolic markers. This multimodal approach is necessary because lowering MRI-visible iron alone has not reliably translated into better movement or daily function. Rare-disease trial-design analysis Precision medicine update (frontiersin.org)

Leading Institutions and Funding

Oregon Health & Science University is a central driver of PKAN metabolic research and led the completed CoA-Z trial, collaborating with Oregon State University, Washington State University, the U.S. Department of Health and Human Services, Spoonbill, and the Spoonbill Foundation. The trial record identifies NIH support through grant R01HD097328, illustrating the importance of public funding and rare-disease philanthropy in moving a naturally occurring metabolic intermediate into human testing. NCT04182763 trial record (ctv.veeva.com)

In the United Kingdom, University College London, the UCL Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital are leading the U.K. 4′-PPT program under Professor Manju Kurian. The registered trial lists Great Ormond Street Children’s Charity and LifeArc as funders. PANK3-activator work has also involved academic drug-discovery teams, including investigators at Yale School of Medicine, while wider NBIA research is coordinated and supported by specialist clinical networks and patient foundations. ISRCTN10664670 trial record VTAC-2 preclinical study (isrctn.com)

Strengths, Limitations, and Challenges

The strongest feature of the current pipeline is its biological logic: 4′-PPT bypasses the PANK2 block directly, while PANK3 activators attempt to restore the same CoA-producing pathway through a functioning related enzyme. These approaches address a probable upstream driver of disease rather than treating only iron deposits or dystonia. The emergence of accessible blood biomarkers may also allow early confirmation that a therapy changes relevant metabolism before researchers wait for slower clinical changes. 4′-PPT mammalian-model study Precision medicine update (link.springer.com)

The limitations are substantial. PKAN is extremely rare, clinically variable, and often diagnosed after neurological injury has accumulated, making small trials difficult to power and making reversal of established disability less likely. Mouse models reproduce important metabolic and retinal features but do not fully reproduce the human neurological syndrome, so biochemical rescue in animals cannot be assumed to predict meaningful functional improvement in patients. Earlier trials also show that favorable effects on brain iron or metabolic measures may not translate into better daily function, and lifelong delivery, blood-brain-barrier exposure, pediatric safety, equitable access, and selection of patients most likely to respond remain unresolved. Precision medicine update Rare-disease trial-design analysis (movementdisorders.onlinelibrary.wiley.com)

Outlook and Future Directions

PKAN is not yet close to a proven cure, but the field is closer to mechanism-based treatment than it was at the start of the decade. The most important milestones to watch are publication of full outcomes from the completed U.S. CoA-Z study, completion of the U.K. 4′-PPT trial in 2027, replication of biomarker changes alongside meaningful functional benefit, and successful translation of VTAC/PANK3 activators or AAV-based PANK2 replacement into human studies. A genuine cure would likely need to restore CoA metabolism early enough to prevent irreversible neuronal loss; therefore, earlier genetic diagnosis, validated biomarkers, and trials that include both classic and atypical PKAN will be as important as the treatment molecules themselves. NCT04182763 trial record ISRCTN10664670 trial record Precision medicine update (ctv.veeva.com)

References

Don't see your disease? Request a report